Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 204

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 204
---
 Statement/Prospectus and the Merger Agreement: “ Acceptable Confidentiality Agreement” means a confidentiality agreement containing confidentiality and use terms not materially less restrictive in the aggregate to the counterparty thereto than the confidentiality and use terms of the Confidentiality Agreement (as defined in the Merger Agreement) (such confidentiality agreement need not contain any “standstill” or similar provisions or otherwise prohibit the making, or amendment, of any Acquisition Proposal); provided, however, that such confidentiality agreement will contain provisions that permit Enfusion to comply with the provisions of Article VIof the Merger Agreement. “ Acquisition Proposal” means any inquiry, offer or proposal from any third party relating to any transaction or series of related transactions involving (i) any acquisition or purchase by any third party, directly or indirectly, of 20% or more of the voting power of the capital stock of Enfusion and its subsidiaries (including securities 130

convertible into or exercisable or exchangeable for equity or voting securities), or any tender offer, exchange offer, share issuance or other similar transaction that, if consummated, would
result in any third party beneficially owning 20% or more of the voting power of the capital stock of Enfusion and its subsidiaries (including securities convertible into or exercisable or exchangeable for equity or voting securities), (ii) any
merger, amalgamation, consolidation, share exchange, business combination, joint venture or other similar transaction involving Enfusion or any of its subsidiaries, pursuant to which a third party would (x) acquire, directly or indirectly, 20%
or more of the consolidated revenues or income or fair market value of the consolidated assets of Enfusion and its subsidiaries, taken as a whole or (y) beneficially own 20% of the voting power of the capital stock of Enfusion (including
securities convertible into or exercisable or exchangeable for equity or voting securities), (iii) any liquidation, dissolution, recapitalization, extraordinary dividend or other significant corporate reorganization of the Enfusion or any of its
subsidiaries, the business of which constitutes 20% or more of the consolidated revenues or income or fair market value of the consolidated assets of Enfusion and its subsidiaries, taken as a whole, (iv) any direct or indirect merger,
consolidation, share exchange, business combination, joint venture, partnership, recapitalization, reorganization or other similar transaction involving Enfusion or any of its subsidiaries, or the surviving entity in such transaction, or resulting
direct